New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
https://patientworthy.com/wp-content/uploads/2018/11/perspective-175642_1280.png

New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!

Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune disorder. It's a rare condition characterized by muscle weakness in the limbs. When the muscle weakness includes the respiratory muscles, the disease can…

Continue Reading New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
kfuhlert / Pixabay

New Approval Gives Juvenile Idiopathic Arthritis Patients More Options

On November 26, 2018, the FDA approved a new autoinjector for individuals with severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular or systemic juvenile idiopathic arthritis (aged 2 and older). It's…

Continue Reading New Approval Gives Juvenile Idiopathic Arthritis Patients More Options
Genome Sequencing Offers Promise for Children with Rare Developmental Delays and Other Genetic Rare Diseases
source: pixabay.com

Genome Sequencing Offers Promise for Children with Rare Developmental Delays and Other Genetic Rare Diseases

  For many families, when their child is born with developmental delays, there may be weeks, months, or even years that go by without a diagnosis. During this time, parents…

Continue Reading Genome Sequencing Offers Promise for Children with Rare Developmental Delays and Other Genetic Rare Diseases
Experimental Treatment for Charcot-Marie-Tooth Disease Gets FDA Fast Track Designation
annca / Pixabay

Experimental Treatment for Charcot-Marie-Tooth Disease Gets FDA Fast Track Designation

According to a story from Digital Journal, the biopharmaceutical company Acceleron Pharma, Inc., recently announced that its investigational drug candidate ACE-083 was granted Fast Track designation from the US Food…

Continue Reading Experimental Treatment for Charcot-Marie-Tooth Disease Gets FDA Fast Track Designation
Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment
mwooten / Pixabay

Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment

According to a story from BioPortfolio, Celgene Corporation and bluebird bio, Inc., have recently announced that enrollment for a pivotal Phase 2 study testing an experimental therapy for relapsed/refractory multiple…

Continue Reading Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment

An Experimental Biopsy Approach Could Improve Diffuse Intrinsic Pontine Glioma Monitoring

According to a story from tgen.org, a team of scientists from the Translational Genomics Research Institute (TGEN) have recently initiated a study that will test the effectiveness of liquid biopsy…

Continue Reading An Experimental Biopsy Approach Could Improve Diffuse Intrinsic Pontine Glioma Monitoring
Researchers Awarded Prize for the Development of Vital Treatment for Spinal Muscular Atrophy
AxxLC / Pixabay

Researchers Awarded Prize for the Development of Vital Treatment for Spinal Muscular Atrophy

According to a story from the Farmington Daily Times, Dr. C. Frank Bennett, who grew up in Aztec, NM, and his collaborator Dr. Adrian Krainer, were both jointly awarded the…

Continue Reading Researchers Awarded Prize for the Development of Vital Treatment for Spinal Muscular Atrophy